Cancer Profiling Market

Cancer Profiling Market (Product: Instruments and Consumables; and Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, and Others - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Cancer Profiling Market Outlook 2031

  • The global industry was valued at US$ 13.4 Bn in 2022
  • It is projected to advance at a CAGR of 10.3% from 2023 to 2031 and reach more than US$ 31.4 Bn by the end of 2031

Analysts’ Viewpoint

Rise in incidence of cancer and growth in investment in cancer research are significant factors fueling cancer profiling market expansion. Increase in demand for consumable products is also anticipated to drive market progress in the near future. Growth in preference for personalized medicine is expected to create lucrative opportunities for market players during the forecast period.

The market for cancer profiling is growing rapidly, driven by advances in technology. Advancements in molecular profiling techniques are providing new opportunities for personalized cancer treatment. Some of the key players are focusing on growth strategies such as mergers & acquisitions and new product launches. They are also increasingly investing in R&D activities to expand their product portfolio.

Cancer Profiling Market

Market Introduction

Cancer profiling is the process of analyzing the molecular and genetic characteristics of cancer. Through this analysis, healthcare providers can develop personalized treatment plans to improve outcomes and minimize side effects.

Cancer profiling involves analyzing cancer cells to identify specific mutations and pathways that are driving tumor growth. It can be used to develop targeted therapies that are more effective and carry fewer side effects than traditional chemotherapy. Tumor profiling can be used to identify the most effective treatment options for individual patients, based on their unique genetic profile.

Rise in Incidence of Cancer Fueling Market Development

The market for cancer profiling is primarily driven by the increase in cancer cases across the globe. Lung cancer, colorectal cancer, breast cancer, and prostate cancer are some of the prominent cancer types affecting the global population.

Incidence and mortality of cancer are increasing consistently across the globe. This can be ascribed to the growth in aging population as well as changes in prevalence and distribution of key risk factors for cancer, some of which are connected to socioeconomic development.

More precise and effective cancer diagnostic techniques are required to locate and categorize cancer cells. The cancer profiling market size is expected to rise significantly in the next few years due to the increase in research and development activities in the area of cancer profiling.

Growth in Investment in Cancer Research to Propel Market Statistics

Various organizations in developed and developing countries are investing significantly in cancer research to explore new treatments, improve patient outcomes, and find a cure for the disease. This can be ascribed to the rise in burden of cancer on individuals, families, and societies across the globe.

In April 2023, a team of researchers from the Leiden University Medical Center (LUMC) received a Euro 3.0 Mn grant on behalf of the Drug Rediscovery Protocol team to tailor cancer treatments based on the genetic makeup of the tumor.

High Demand for Consumable Products Creating Lucrative Cancer Profiling Market Opportunities

Based on product, the consumables segment accounted for major market share in 2022 due to the increase in usage of consumables in day-to-day operations in cancer profiling labs.

Consumable products that are used in cancer profiling include a wide range of reagents and assay components such as antibodies, buffers, enzymes, and probes. These products are used in various cancer profiling methods, such as genomic profiling, proteomic profiling, and imaging techniques, to analyze the molecular characteristics of cancer cells.

Consumable products are required for every step of the cancer profiling process, from sample preparation to data analysis. According to a cancer profiling market research report, demand for consumable products is estimated to rise significantly in the near future.

Surge in Adoption of Polymerase Chain Reaction Technology

Polymerase chain reaction (PCR) is a leading technology for cancer profiling due to its high sensitivity and specificity in detecting specific DNA sequences. PCR is a widely used molecular biology technique that amplifies a specific segment of DNA, allowing for the detection and quantification of a specific gene or mutation associated with cancer.

Polymerase chain reaction can be used to detect specific mutations or alterations in cancer cells, providing valuable information for diagnosis, prognosis, and treatment. For instance, PCR can be used to detect specific genetic mutations in tumor DNA that are associated with specific cancer types, such as mutations in the KRAS gene that are commonly found in pancreatic cancer. Rise in adoption of PCR technology is contributing to the market growth.

Increase in Prevalence of Lung Cancer Augmenting Cancer Profiling Market Growth

As per cancer profiling market analysis, rise in prevalence of lung cancer is a key factor boosting industry dynamics. Lung cancer is the second most common cancer worldwide. It is the most common cancer in men and the second most common cancer in women.

Lung cancer is the primary cause of cancer-related deaths worldwide. Incidence of this type of cancer is expected to continue to rise in the next few years. However, development of new treatments, such as immunotherapies and targeted therapies, has improved the survival rate and management of lung cancer patients.

Increase in usage of screening and early detection methods are likely to boost cancer profiling market demand during the forecast period.

Regional Outlook of Global Cancer Profiling Industry

According to the cancer profiling market report, North America is projected to dominate the global landscape during the forecast period.

Cancer incidences are rising significantly in North America owing to growth in aging population, high rate of obesity, and environmental factors. The region is likely to account for significant cancer profiling market share in the near future.

According to the cancer profiling market research, breast cancer, lung cancer, prostate cancer, and colorectal cancer are the most common types of cancer in North America.

Analysis of Key Players in Global Cancer Profiling Market

Abbott Laboratories, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, HTG Molecular Diagnostics, Inc., Illumina, Inc., PerkinElmer Inc., QIAGEN N.V., Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., Hologic, Inc., and Guardant Health are some of the prominent players in the global market.

Each of these players has been profiled in the cancer profiling market forecast report based on parameters such as product portfolio, recent developments, financial overview, company overview, business strategies, and business segments. Leading cancer profiling companies are engaged in strategic acquisitions and partnerships to strengthen their market position.

Key Developments

  • In April 2023, Agilent Technologies Inc. collaborated with South Korea-based Theragen Bio to improve its precision oncology methods by using advanced bioinformatic (BI) solutions. Agilent Technologies Inc. and Theragen Bio would combine their respective strengths in cancer genomic profiling (CGP) design, engineering knowledge, and software skills to accelerate localized analysis capabilities and treatment decisions.
  • In July 2022, Guardant Health, a precision oncology company in the U.S., entered into a strategic partnership with Adicon Holdings Limited, an independent clinical laboratory (ICL) company based in China. The partnership would allow biopharmaceutical companies to conduct clinical trials in China by accessing Guardant Health's comprehensive genomic profiling (CGP) tests.

Market Snapshot

Attribute Detail

Market Value in 2022

US$ 13.4 Bn

Forecast Value in 2031

More than US$ 31.4 Bn

Growth Rate (CAGR)

10.3%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Product
    • Instruments
      • Immunohistochemistry Analyzers
      • In Situ Hybridization Instruments
      • Polymerase Chain Reaction Instruments
      • DNA Sequencers
      • Fragment Analyzers
    • Consumables
      • Reagents & Kits
      • Others
  • Technology
    • Immunohistochemistry
    • Next Generation Sequencing
    • Polymerase Chain Reaction
    • In Situ Hybridization
    • Microarrays
    • Fragment Analysis
    • Others
  • Cancer Type
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma
    • Others
  • End-user
    • Hospitals
    • Diagnostic Centers
    • Cancer Research Institutes
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • F. Hoffmann-La Roche Ltd
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Hologic, Inc.
  • Guardant Health

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global cancer profiling market in 2022?

It was valued at US$ 13.4 Bn in 2022

How big will the cancer profiling industry be by 2031?

It is projected to reach more than US$ 31.4 Bn by 2031

What will be the CAGR of the cancer profiling business during the forecast period?

The CAGR is anticipated to be 10.3% from 2023 to 2031

What are the prominent factors fueling demand for cancer profiling?

Increase in prevalence of cancer and growth in investment in cancer research

What was the share of the leading product segment of cancer profiling in 2022?

The consumables product segment accounted for more than 60.0% share in 2022

Which region is expected to account for major share of cancer profiling during the forecast period?

North America is likely to constitute the largest share from 2023 to 2031

Who are the prominent cancer profiling companies?

Abbott Laboratories, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, HTG Molecular Diagnostics, Inc., Illumina, Inc., PerkinElmer Inc., QIAGEN N.V., Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., Hologic, Inc., and Guardant Health

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Cancer Profiling Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Cancer Profiling Market Analysis and Forecast, 2017-2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Regulatory Scenario for Cancer Profiling

        5.2. Cancer Epidemiology, by Region

        5.3. Technological Advancements in Cancer Profiling Technology

        5.4. COVID-19 Impact on the Industry

    6. Global Cancer Profiling Market Analysis and Forecast, by Product

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Product, 2017-2031

            6.3.1. Instruments

                6.3.1.1. Immunohistochemistry Analyzers

                6.3.1.2. In Situ Hybridization Instruments

                6.3.1.3. Polymerase Chain Reaction Instruments

                6.3.1.4. DNA Sequencers

                6.3.1.5. Fragment Analyzers

            6.3.2. Consumables

                6.3.2.1. Reagents & Kits

                6.3.2.2. Others

        6.4. Market Attractiveness Analysis, by Product

    7. Global Cancer Profiling Market Analysis and Forecast, by Technology

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Technology, 2017-2031

            7.3.1. Immunohistochemistry

            7.3.2. Next Generation Sequencing

            7.3.3. Polymerase Chain Reaction

            7.3.4. In Situ Hybridization

            7.3.5. Microarrays

            7.3.6. Fragment Analysis

            7.3.7. Others

        7.4. Market Attractiveness Analysis, by Technology

    8. Global Cancer Profiling Market Analysis and Forecast, by Cancer Type

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Cancer Type, 2017-2031

            8.3.1. Breast Cancer

            8.3.2. Lung Cancer

            8.3.3. Colorectal Cancer

            8.3.4. Prostate Cancer

            8.3.5. Prostate Cancer

            8.3.6. Melanoma

            8.3.7. Others

        8.4. Market Attractiveness Analysis, by Cancer Type

    9. Global Cancer Profiling Market Analysis and Forecast, by End-user

        9.1. Introduction & Definition

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by End-user, 2017-2031

            9.3.1. Hospitals

            9.3.2. Diagnostic Centers

            9.3.3. Cancer Research Institutes

            9.3.4. Others

        9.4. Market Attractiveness Analysis, by End-user

    10. Global Cancer Profiling Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region, 2017-2031

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness By Country/Region

    11. North America Cancer Profiling Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2017-2031

            11.2.1. Instruments

                11.2.1.1. Immunohistochemistry Analyzers

                11.2.1.2. In Situ Hybridization Instruments

                11.2.1.3. Polymerase Chain Reaction Instruments

                11.2.1.4. DNA Sequencers

                11.2.1.5. Fragment Analyzers

            11.2.2. Consumables

                11.2.2.1. Reagents & Kits

                11.2.2.2. Others

        11.3. Market Value Forecast, by Technology, 2017-2031

            11.3.1. Immunohistochemistry

            11.3.2. Next Generation Sequencing

            11.3.3. Polymerase Chain Reaction

            11.3.4. In Situ Hybridization

            11.3.5. Microarrays

            11.3.6. Fragment Analysis

            11.3.7. Others

        11.4. Market Value Forecast, by Cancer Type, 2017-2031

            11.4.1. Breast Cancer

            11.4.2. Lung Cancer

            11.4.3. Colorectal Cancer

            11.4.4. Prostate Cancer

            11.4.5. Prostate Cancer

            11.4.6. Melanoma

            11.4.7. Others

        11.5. Market Value Forecast, by End-user, 2017-2031

            11.5.1. Hospitals

            11.5.2. Diagnostic Centers

            11.5.3. Cancer Research Institutes

            11.5.4. Others

        11.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Product

            11.7.2. By Technology

            11.7.3. By Cancer Type

            11.7.4. By End-user

            11.7.5. By Country

    12. Europe Cancer Profiling Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2017-2031

            12.2.1. Instruments

                12.2.1.1. Immunohistochemistry Analyzers

                12.2.1.2. In Situ Hybridization Instruments

                12.2.1.3. Polymerase Chain Reaction Instruments

                12.2.1.4. DNA Sequencers

                12.2.1.5. Fragment Analyzers

            12.2.2. Consumables

                12.2.2.1. Reagents & Kits

                12.2.2.2. Others

        12.3. Market Value Forecast, by Technology, 2017-2031

            12.3.1. Immunohistochemistry

            12.3.2. Next Generation Sequencing

            12.3.3. Polymerase Chain Reaction

            12.3.4. In Situ Hybridization

            12.3.5. Microarrays

            12.3.6. Fragment Analysis

            12.3.7. Others

        12.4. Market Value Forecast, by Cancer Type, 2017-2031

            12.4.1. Breast Cancer

            12.4.2. Lung Cancer

            12.4.3. Colorectal Cancer

            12.4.4. Prostate Cancer

            12.4.5. Prostate Cancer

            12.4.6. Melanoma

            12.4.7. Others

        12.5. Market Value Forecast, by End-user, 2017-2031

            12.5.1. Hospitals

            12.5.2. Diagnostic Centers

            12.5.3. Cancer Research Institutes

            12.5.4. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Italy

            12.6.5. Spain

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Product

            12.7.2. By Technology

            12.7.3. By Cancer Type

            12.7.4. By End-user

            12.7.5. By Country/Sub-region

    13. Asia Pacific Cancer Profiling Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2017-2031

            13.2.1. Instruments

                13.2.1.1. Immunohistochemistry Analyzers

                13.2.1.2. In Situ Hybridization Instruments

                13.2.1.3. Polymerase Chain Reaction Instruments

                13.2.1.4. DNA Sequencers

                13.2.1.5. Fragment Analyzers

            13.2.2. Consumables

                13.2.2.1. Reagents & Kits

                13.2.2.2. Others

        13.3. Market Value Forecast, by Technology, 2017-2031

            13.3.1. Immunohistochemistry

            13.3.2. Next Generation Sequencing

            13.3.3. Polymerase Chain Reaction

            13.3.4. In Situ Hybridization

            13.3.5. Microarrays

            13.3.6. Fragment Analysis

            13.3.7. Others

        13.4. Market Value Forecast, by Cancer Type, 2017-2031

            13.4.1. Breast Cancer

            13.4.2. Lung Cancer

            13.4.3. Colorectal Cancer

            13.4.4. Prostate Cancer

            13.4.5. Prostate Cancer

            13.4.6. Melanoma

            13.4.7. Others

        13.5. Market Value Forecast, by End-user, 2017-2031

            13.5.1. Hospitals

            13.5.2. Diagnostic Centers

            13.5.3. Cancer Research Institutes

            13.5.4. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Product

            13.7.2. By Technology

            13.7.3. By Cancer Type

            13.7.4. By End-user

            13.7.5. By Country/Sub-region

    14. Latin America Cancer Profiling Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Product, 2017-2031

            14.2.1. Instruments

                14.2.1.1. Immunohistochemistry Analyzers

                14.2.1.2. In Situ Hybridization Instruments

                14.2.1.3. Polymerase Chain Reaction Instruments

                14.2.1.4. DNA Sequencers

                14.2.1.5. Fragment Analyzers

            14.2.2. Consumables

                14.2.2.1. Reagents & Kits

                14.2.2.2. Others

        14.3. Market Value Forecast, by Technology, 2017-2031

            14.3.1. Immunohistochemistry

            14.3.2. Next Generation Sequencing

            14.3.3. Polymerase Chain Reaction

            14.3.4. In Situ Hybridization

            14.3.5. Microarrays

            14.3.6. Fragment Analysis

            14.3.7. Others

        14.4. Market Value Forecast, by Cancer Type, 2017-2031

            14.4.1. Breast Cancer

            14.4.2. Lung Cancer

            14.4.3. Colorectal Cancer

            14.4.4. Prostate Cancer

            14.4.5. Prostate Cancer

            14.4.6. Melanoma

            14.4.7. Others

        14.5. Market Value Forecast, by End-user, 2017-2031

            14.5.1. Hospitals

            14.5.2. Diagnostic Centers

            14.5.3. Cancer Research Institutes

            14.5.4. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Product

            14.7.2. By Technology

            14.7.3. By Cancer Type

            14.7.4. By End-user

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Cancer Profiling Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Product, 2017-2031

            15.2.1. Instruments

                15.2.1.1. Immunohistochemistry Analyzers

                15.2.1.2. In Situ Hybridization Instruments

                15.2.1.3. Polymerase Chain Reaction Instruments

                15.2.1.4. DNA Sequencers

                15.2.1.5. Fragment Analyzers

            15.2.2. Consumables

                15.2.2.1. Reagents & Kits

                15.2.2.2. Others

        15.3. Market Value Forecast, by Technology, 2017-2031

            15.3.1. Immunohistochemistry

            15.3.2. Next Generation Sequencing

            15.3.3. Polymerase Chain Reaction

            15.3.4. In Situ Hybridization

            15.3.5. Microarrays

            15.3.6. Fragment Analysis

            15.3.7. Others

        15.4. Market Value Forecast, by Cancer Type, 2017-2031

            15.4.1. Breast Cancer

            15.4.2. Lung Cancer

            15.4.3. Colorectal Cancer

            15.4.4. Prostate Cancer

            15.4.5. Prostate Cancer

            15.4.6. Melanoma

            15.4.7. Others

        15.5. Market Value Forecast, by End-user, 2017-2031

            15.5.1. Hospitals

            15.5.2. Diagnostic Centers

            15.5.3. Cancer Research Institutes

            15.5.4. Others

        15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Product

            15.7.2. By Technology

            15.7.3. By Cancer Type

            15.7.4. By End-user

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (By Tier and Size of Companies)

        16.2. Market Share Analysis, by Company (2022)

        16.3. Company Profiles

            16.3.1. Abbott Laboratories

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Product Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. Agilent Technologies Inc.

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Product Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. F. Hoffmann-La Roche Ltd

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Product Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. HTG Molecular Diagnostics, Inc.

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Product Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. Illumina, Inc.

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Product Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

                16.3.5.5. Strategic Overview

            16.3.6. PerkinElmer Inc.

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Product Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

                16.3.6.5. Strategic Overview

            16.3.7. QIAGEN N.V.

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Product Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

                16.3.7.5. Strategic Overview

            16.3.8. Siemens Healthineers

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Product Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

                16.3.8.5. Strategic Overview

            16.3.9. Sysmex Corporation

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Product Portfolio

                16.3.9.3. Financial Overview

                16.3.9.4. SWOT Analysis

                16.3.9.5. Strategic Overview

            16.3.10. Thermo Fisher Scientific Inc.

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Product Portfolio

                16.3.10.3. Financial Overview

                16.3.10.4. SWOT Analysis

                16.3.10.5. Strategic Overview

            16.3.11. Hologic, Inc.

                16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.11.2. Product Portfolio

                16.3.11.3. Financial Overview

                16.3.11.4. SWOT Analysis

                16.3.11.5. Strategic Overview

            16.3.12. Guardant Health

                16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.12.2. Product Portfolio

                16.3.12.3. Financial Overview

                16.3.12.4. SWOT Analysis

                16.3.12.5. Strategic Overview

    List of Tables

    Table 01: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 02: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments, 2017-2031

    Table 03: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031

    Table 03: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 04: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031

    Table 05: Global Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 06: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 07: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 08: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 09: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments, 2017-2031

    Table 10: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031

    Table 11: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 12: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031

    Table 13: North America Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 14: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 15: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 16: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments, 2017-2031

    Table 17: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031

    Table 18: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 19: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031

    Table 20: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 21: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 23: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 24: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Indication, 2017-2031

    Table 25: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Therapy, 2017-2031

    Table 26: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 27: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 28: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 29: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments 2017-2031

    Table 30: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031

    Table 31: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 32: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031

    Table 34: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 35: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 36: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 37: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments, 2017-2031

    Table 38: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031

    Table 39: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 40: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031

    Table 41: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    List of Figures

    Figure 01: Global Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031

    Figure 02: Global Cancer Profiling Market Attractiveness Analysis, Product, 2022-2031

    Figure 03: Global Cancer Profiling Market (US$ Mn), by Instrument, 2017-2031

    Figure 04: Global Cancer Profiling Market (US$ Mn), by Immunohistochemistry Analyzers, 2017-2031

    Figure 05: Global Cancer Profiling Market (US$ Mn), by In Situ Hybridization Instruments, 2017-2031

    Figure 06: Global Cancer Profiling Market (US$ Mn), by Polymerase Chain Reaction Instruments, 2017-2031

    Figure 07: Global Cancer Profiling Market (US$ Mn), by DNA Sequencers, 2017-2031

    Figure 08: Global Cancer Profiling Market (US$ Mn), by Fragment Analyzers, 2017-2031

    Figure 09: Global Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 10: Global Cancer Profiling Market Attractiveness Analysis, Technology, 2022-2031

    Figure 11: Global Cancer Profiling Market (US$ Mn), by Immunohistochemistry, 2017-2031

    Figure 12: Global Cancer Profiling Market (US$ Mn), by Next Generation Sequencing, 2017-2031

    Figure 13: Global Cancer Profiling Market (US$ Mn), by Polymerase Chain Reaction, 2017-2031

    Figure 14: Global Cancer Profiling Market (US$ Mn), by In Situ Hybridization, 2017-2031

    Figure 15: Global Cancer Profiling Market (US$ Mn), by Microarrays, 2017-2031

    Figure 16: Global Cancer Profiling Market (US$ Mn), by Fragment Analysis, 2017-2031

    Figure 17: Global Cancer Profiling Market (US$ Mn), by Others, 2017-2031

    Figure 18: Global Cancer Profiling Market Value Share Analysis, by Cancer Type 2021 and 2031

    Figure 19: Global Cancer Profiling Market Attractiveness Analysis, Cancer Type, 2022-2031

    Figure 20: Global Cancer Profiling Market (US$ Mn), by Breast Cancer, 2017-2031

    Figure 21: Global Cancer Profiling Market (US$ Mn), by Lung Cancer, 2017-2031

    Figure 22: Global Cancer Profiling Market (US$ Mn), by Colorectal Cancer, 2017-2031

    Figure 23: Global Cancer Profiling Market (US$ Mn), by Prostate Cancer, 2017-2031

    Figure 24: Global Cancer Profiling Market (US$ Mn), by Melanoma, 2017-2031

    Figure 25: Global Cancer Profiling Market (US$ Mn), by Others, 2017-2031

    Figure 26: Global Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 27: Global Cancer Profiling Market Attractiveness Analysis, End-user, 2022-2031

    Figure 28: Global Cancer Profiling Market (US$ Mn), by Hospitals, 2017-2031

    Figure 29: Global Cancer Profiling Market (US$ Mn), by Diagnostic Centers, 2017-2031

    Figure 30: Global Cancer Profiling Market (US$ Mn), by Cancer Research Institutes, 2017-2031

    Figure 31: Global Cancer Profiling Market (US$ Mn), by Others, 2017-2031

    Figure 32: Global Cancer Profiling Market Attractiveness Analysis, by Region, 2022-2031

    Figure 33: Global Cancer Profiling Market Value Share Analysis, by Region, 2021 and 2031

    Figure 34: Global Cancer Profiling Market Attractiveness Analysis, by Region, 2022-2031

    Figure 35: North America Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 36: North America Cancer Profiling Market Value Share Analysis, by Country, 2021 and 2031

    Figure 37: North America Cancer Profiling Market Attractiveness, by Country, 2022-2031

    Figure 38: North America Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031

    Figure 39: North America Cancer Profiling Market Attractiveness, by Product, 2022-2031

    Figure 40: North America Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 41: North America Cancer Profiling Market Attractiveness, by Technology, 2022-2031

    Figure 42: North America Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031

    Figure 43: North America Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031

    Figure 44: North America Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 45: North America Cancer Profiling Market Attractiveness, by End-user, 2022-2031

    Figure 46: Europe Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 47: Europe Cancer Profiling Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 48: Europe Cancer Profiling Market Attractiveness, by Country/Sub-region, 2022-2031

    Figure 49: Europe Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031

    Figure 50: Europe Cancer Profiling Market Attractiveness, by Product, 2022-2031

    Figure 51: Europe Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 52: Europe Cancer Profiling Market Attractiveness, by Technology, 2022-2031

    Figure 53: Europe Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031

    Figure 54: Europe Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031

    Figure 55: Europe Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 56: Europe Cancer Profiling Market Attractiveness, by End-user, 2022-2031

    Figure 57: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 58: Asia Pacific Cancer Profiling Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 59: Asia Pacific Cancer Profiling Market Attractiveness, by Country/Sub-region, 2022-2031

    Figure 60: Asia Pacific Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031

    Figure 61: Asia Pacific Cancer Profiling Market Attractiveness, by Product, 2022-2031

    Figure 62: Asia Pacific Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 63: Asia Pacific Cancer Profiling Market Attractiveness, by Technology, 2022-2031

    Figure 64: Asia Pacific Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031

    Figure 65: Asia Pacific Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031

    Figure 66: Asia Pacific Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 67: Asia Pacific Cancer Profiling Market Attractiveness, by End-user, 2022-2031

    Figure 68: Latin America Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 69: Latin America Cancer Profiling Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 70: Latin America Cancer Profiling Market Attractiveness, by Country/Sub-region, 2022-2031

    Figure 71: Latin America Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031

    Figure 72: Latin America Cancer Profiling Market Attractiveness, by Product, 2022-2031

    Figure 73: Latin America Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 74: Latin America Cancer Profiling Market Attractiveness, by Technology, 2022-2031

    Figure 75: Latin America Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031

    Figure 76: Latin America Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031

    Figure 77: Latin America Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 78: Latin America Cancer Profiling Market Attractiveness, by End-user, 2022-2031

    Figure 79: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 80: Middle East & Africa Cancer Profiling Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 81: Middle East & Africa Cancer Profiling Market Attractiveness, by Country/Sub-region, 2022-2031

    Figure 82: Middle East & Africa Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031

    Figure 83: Middle East & Africa Cancer Profiling Market Attractiveness, by Product, 2022-2031

    Figure 84: Middle East & Africa Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 85: Middle East & Africa Cancer Profiling Market Attractiveness, by Technology, 2022-2031

    Figure 86: Middle East & Africa Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031

    Figure 87: Middle East & Africa Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031

    Figure 88: Middle East & Africa Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 89: Middle East & Africa Cancer Profiling Market Attractiveness, by End-user, 2022-2031

    Figure 90: Global Cancer Profiling Market Share Analysis, by Company 2022

Copyright © Transparency Market Research, Inc. All Rights reserved